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and Chronic Congestive Heart Failure
KANU CHATTERJEE, MB, FRCP, FACC, WILLIAM W. PARMLEY, MD, FACC
San Francisco, California
Vasodilator therapy is useful adjunctive therapy in the
management of both acute and chronic heart failure.
Arteriolar dilators, such as hydralazine, increase cardiac
output by decreasing the elevated peripheral vascular
resistance that occurs in heart failure. Venodilators, such
as nitrates, decrease ventricular filling pressures by re-
distributing blood so that more is pooled in peripheral
veins. Vasodilators that produce both effects (nitro-
prusside, prazosin, captopril, for example) are usually
helpful in short-term improvement of hemodynamics.
Long-term treatment with nonparenteral vasodilators
often reduces symptoms and increases exercise toler-
The potential benefits of vasodilation in the treatment of
heart failure were observed more than 3 decades ago (1-
3). However, it was not until the late I960s and early 1970s
that vasodilator therapy was shown to produce marked im-
provement in the cardiac performance of patients with acute
or chronic heart failure (4-8) or mitral regurgitation (9).
This renewed interest in vasodilator therapy was closely
linked to the development of newer techniques for bedside
hemodynamic monitoring. Use of balloon flotation catheters
(10,11) has facilitated evaluation of the hemodynamic ef-
fects of a variety of vasodilator drugs and their application
to the management of critically ill patients. Since the rec-
ognition of the potential benefits of vasodilators, there has
been increasing interest in delineating their mechanisms of
action, their effects on cardiac dynamics and regional cir-
culations and their relative advantages and disadvantages.
Furthermore, the search continues to identify newer, better
vasodilator drugs for the treatment of heart failure. The
purpose of this paper is to provide an overview of vasodilator
therapy for heart failure, and to describe in detail some of
the specific effects of the currently available drugs. Because
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ance, although there is inconclusive evidence regarding
the effects of these agents on mortality. In acute myo-
cardial infarction, intravenous vasodilators frequently
improve cardiac performance. Evidence regarding their
beneficial effects on infarct size and immediate mortality
is encouraging but inconclusive. There is little evidence
that they prolong life in patients who survive cardiogenic
shock and leave the hospital. Thus, vasodilators can im-
prove hemodynamics and lessen symptoms, but more
evidence is needed regarding their long-term effects on
survival.
this is a rapidly changing field, no attempt will be made to
provide all-inclusive information: instead, areas of practical
and clinical interest will be emphasized.
Mechanisms of Action
After/oad Reduction
Vasodilator therapy for low cardiac output is based on the
principle of afterload reduction in the failing heart. From
studies of the mechanics of contraction of isolated heart
muscle, it is known that increasing the load against which
a muscle shortens (afterload) will decrease the magnitude
of shortening and the velocity of shortening (12). Con-
versely, if one reduces the afterload, the muscle shortens
further and with a greater velocity. Translation of this con-
cept to the intact heart explains how decreased resistance
to left ventricular ejection can enhance shortening of cardiac
muscle fibers and thereby increase stroke volume and car-
diac output.
In isolated heart muscle preparations, preload represents
the initial load on the muscle that stretches it to its end-
diastolic length before contraction. Afterload represents the
additional load the muscle must lift as it shortens. If the
concepts of preload and afterload, as defined in isolated
muscle experiments, are used in the intact heart. it is nec-
essary to calculate instantaneous wall stress from measure-
ments of intraventricular pressure, radius and wall thickness
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(l3.I 4). However, such calculations are difficult to make
in clinical practice. Therefore, other approximations of af-
terload, such as aortic pressure, aortic impedance and sys-
temic vascular resistance, have been used.
Arterial pressure. Arterial pressure is the most easily
measured index of afterload in the intact heart, because the
left ventricle must generate that pressure before it can open
the aortic valve. Increased intraventricular systolic pressure
(aortic pressure in the absence of left ventricular outflow
obstruction) is associated with decreased shortening of the
left ventricular diameter during systole, and decreased mean
velocity of circumferential shortening (VC F ) (14-16). Ar-
terial pressure, however, should be regarded as a rough
approximation of afterload, because it is only one of the
variables that determines wall stress. Furthermore, changes
in arterial pressure may not appropriately reflect changes in
cardiac performance during vasodilator therapy. In certain
circumstances, arterial pressure may not change when a
vasodilator-induced decrease in systemic vascular resistance
causes a proportional increase in cardiac output. This reflects
the basic relation between blood pressure (BP), cardiac out-
put (CO) and systemic vascular resistance (SVR): BP =
CO x SVR.
Aortic input impedance. Some investigators believe that
the external force to ventricular ejection (afterload) is better
represented by the aortic input impedance, which can be
described by the relation of aortic pulsatile pressure and
flow waveforms throughout the cardiac cycle (17-25). In
general, "impedance" implies a measure of the opposition
to flow presented by a system and is a frequency-dependent
function. Resistance conveys a meaning similar to imped-
ance but is confined to average or steady state conditions.
In the arterial system, blood pressure and flow exist as
oscillatory (or pulsatile) waveforms superimposed on a mean
(or nonpulsatile) component. Thus, total opposition to ar-
terial blood flow encompasses both frequency-dependent
pulsatile components and a frequency-independent nonpul-
satile steady state component. Aortic input impedance pro-
vides information about both pulsatile and nonpulsatile com-
ponents of the vascular load (17,19,24,25). The influence
of each individual component of vascular load on ventricular
ejection has been evaluated in experimental animals and
human beings. Decreased arterial compliance (increased
characteristic impedance) with constant resistance is asso-
ciated with reduced stroke volume and mean aortic pressure
(23). Increased resistance alone also causes a decrease in
stroke volume but increases mean aortic pressure.
Aortic input impedance spectra were determined in pa-
tients with clinical and hemodynamic evidence of chronic
heart failure and compared with those in subjects without
heart failure, matched for age and arterial pressure. In pa-
tients with heart failure, both input resistance and charac-
teristic impedance (index of aortic distensibility) were sig-
nificantly greater than values in control subjects (26). It was
also demonstrated that vasodilators like sodium nitroprus-
side can decrease characteristic impedance and increase ven-
tricular ejection without changing arterial pressure (27). These
studies indicate that a vasodilator-induced increase in ar-
terial compliance is a potentially important mechanism for
improving left ventricular function during vasodilator ther-
apy. The calculation of aortic input impedance, however,
is difficult and cannot be applied in routine clinical practice.
Systemic vascular resistance. Systemic vascular resis-
tance, which can be determined more easily, is related to
aortic input impedance. Whereas impedance is the instan-
taneous relation between pressure and flow, systemic vas-
cular resistance is the average of this relation throughout
the cardiac cycle. Systemic resistance is the ratio of the
reduction in pressure drop across the arterial system and the
mean flow. The use of systemic vascular resistance to rep-
resent afterload not only is helpful in understanding how
vasodilators improve cardiac function but also can be ap-
plied in clinical practice (28). Reduction of systemic vas-
cular resistance or aortic impedance appears to be the prin-
cipal mechanism for the improvement of left ventricular
function with vasodilators (Fig. I) (29,30).
Relief of myocardial ischemia. A number of investi-
gations have shown that relief of segmental myocardial
ischemia might also be beneficial (31-34). Vasodilator agents
can decrease myocardial oxygen requirements in heart fail-
ure by decreasing the determinants of myocardial oxygen
demand. Intraventricular pressure and ventricular volume
decrease, the heart rate either decreases or remains un-
changed, and most vasodilator agents do not possess any
direct positive inotropic effects. Thus, the overall myo-
cardial oxygen demand tends to decrease during vasodilator
therapy. Some vasodilator agents may also increase regional
myocardial perfusion by enhancing collateral blood flow to
ischemic myocardial segments (34,35). Furthermore, im-
proved subendocardial blood flow has been demonstrated
in heart failure due to experimental myocardial infarction,
presumably as a result of an increased transmyocardial pres-
sure gradient (aortic diastolic pressure-left ventricular di-
astolic pressure) or of increased collateral flow (36,37). It
appears, therefore, that vasodilators have the potential to
decrease segmental myocardial ischemia by decreasing
myocardial oxygen requirements or increasing myocardial
perfusion, or both. This net decrease in segmental myo-
cardial ischemia might improve overall cardiac perfor-
mance; supporting evidence is available from ventriculo-
graphic and radioisotope angiographic studies in patients
with acute myocardial infarction as well as in patients with
chronic coronary artery disease without heart failure
(32,33,38,39).
Left ventricular diastolic compliance. Another possi-
ble mechanism by which vasodilators can produce beneficial
effects in patients with heart failure is by increasing left
ventricular diastolic compliance. The pressure-volume re-
lation of the left ventricle is curvilinear, so that at small
end-diastolic volumes, a given volume increment will pro-
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Figure I. Left ventricular function curves plotting stroke volume versus
left ventricular filling pressure are illustrated under control conditions and
after decreased aortic impedance or increased aortic impedance. At a high
filling pressure (20 mm Hg). with a decrease in impedance. there i, a
decrease in filling pressure to 15 mm Hg (line A) and an increase in stroke
volume. Beginning at a low ventricular filling pressure (10 mm Hg) , there
is a similar reduction in the magnitude of tilling pressure. bUI this i,
accompanied by a reduction in stroke volume (line BI. This graph con-
ceptually illustrates the importance of giving vasodilators only to patients
with high left ventricular filling pressures. (Reprinted from Chatterjee K.
Parmley WW [30]. with permission.)
duce only a minor rise in ventricular diastolic pressure. At
high end-diastolic volumes. as in patients with heart failure.
however. there is a greater increase in diastolic pressure
with each volume increment as the ventricle moves onto the
steep portion of its curve. Because left ventricular end-
diastolic volume is the most important determinant of stroke
volume, it is apparent that a shift in ventricular compliance
could markedly alter the relation between filling pressure
and cardiac performance. Thus, if the pressure-volume re-
lation were shifted to the right-that is. if there was a larger
volume at the same end-diastolic pressure-a leftward shift
of the left ventricular function curve might result. such as
that seen with vasodilators.
Eviden ce suggests that vasodilator drugs may produce
all acute increase ill left ventricular compliance (40-42) .
In general. drugs that lower aortic and pulmonary artery
pressures increase compliance, while those that raise pres-
sures tend to decrease compliance. There has been consid-
erable speculation as to the mechanism of these effects.
Some investigators (43) have said that the increase in com-
pliance produced by vasodilators may be due to a reduction
in ischemia and relief of ischemic contracture. Others (40)
have suggested that this change in compliance is a result of
the interaction of the right and left ventricles in a confined
pericardial space. Because the pericardium is a very stiff
structure. at high filling pressures it tends to maintain a
constant overall heart volume. A vasodilator that reduces
right-sided pressures will also reduce the end-diastolic vol-
ume of the right ventricle and allow for a larger left ventricle
at the same left ventricular diastolic pressure. Thus. agents
that lower right-sided pressures will tend to produce an
apparent increase in the compliance of the left ventricle and
a beneficial shift in the ventricular function curve. This
mechanism has been carefully described in experimental
studies with animals. and there are enough clinical data to
suggest that it is of some value in the clinical situation. but
further studies are required to assess the relative importance
of its role.
Overall. it is apparent that the vasodilators call improve
left ventricular function ofpatients with heart failure by a
number ofrelated mechanisms . The most important of these
appears to be the reduction of left ventricular ejection imped-
ance. although relief of segmental myocardial ischemia and
an increase in ventricular compliance may also play signif-
icant roles in certain circumstances.
Mechanism of Systemic Vasoconstriction in
Heart Failure
Catecholamine release. The mediators of the systemic
vasomotor response to heart failure have been discussed in
recent review articles (44,45). An understanding of the
different mechanisms that contribute to vasoconstriction and
maintain an elevated systemic vascular resistance has im-
portant implications regarding the mechanisms of vasodi-
lation and the hemodynamic effects of the different vaso-
dilator agents. In patients with severe heart failure associated
with a reduced cardiac output. systemic vascular resistance
is markedly elevated (46-48). It appears that this vasocon-
striction results from increased stimulation of vascularalphal-
receptors due in part to neurogenic mechanisms as well as
to high levels of circulating norepinephrine. Circulating nor-
epinephrine levels are frequently elevated in patients with
heart failure (Table I) (49-52). and it has been postulated
that this results primarily from spillover into the circulation
of catecholamines released during peripheral neurogenic
vasoconstriction.
Angiotensin II. In addition to increasing levels of cir-
culating norepinephrine. angiotensin II contributes to an
elevated systemic vascular resistance (53-63). The precise
mechanism for the activation of the renin-angiotensin-al-
dosterone system in heart failure is not entirely known.
Increased renal sympathetic activity with beta-receptor stim-
ulation, renal vasoconstriction with redistribution of cortical
blood flow to medullary glomeruli and a reduction in per-
fusion pressure in the afferent arterioles-all can promote
renin release from the juxtaglomerular apparatus. Irrespec-
tive of the mechanism. increased renin release is accom-
panied by increased levels of angiotensin II. which elevate
systemic vascular resistance. Angiotensin also facilitates
norepinephrine release at neuromuscular junctions and thus
further contributes to the increase in systemic vascular re-
sistance. Increased aldosterone levels promote salt and water
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Classification and Hemodynamic
Effects of Vasodilators
Table 1. Plasma Catecholamine Levels and Hemodynamics at
Rest in Patients With Severe Chronic Ischemic Cardiomyopathy
and Patients With Coronary Artery Disease Without Heart
Failure
Classification
Primary effects. A number of vasodilator agents de-
crease vascular tone by direct relaxation of the smooth mus-
cle of the peripheral vascular bed. Nitroprusside. nitroglyc-
erin and other organic nitrates. molsidornine, hydralazine
retention with consequent deterioration in heart failure. In
some patients with severe heart failure, angiotensin II con-
tributes significantly to elevating systemic vascular resis-
tance. When these patients are treated with angiotensin-
converting enzyme inhibitors, systemic vascular resistance
decreases and renal function and cardiac function improve.
Vasopressin. In many patients with chronic heart fail-
ure. a higher level of the antidiuretic hormone. vasopressin,
has been observed (64,65). The increase in vasopressin oc-
curs despite cardiac dilation and left atrial stretching, which
usually inhibits the secretion of antidiuretic hormone. The
significance of this increase is not apparent; however, it
might contribute to plasma volume expansion and to the
increase in systemic vascular resistance.
Increased vascular stiffness. Increased vascular stiff-
ness in congestive heart failure has been considered an im-
portant contributing factor in elevating systemic vascular
resistance (44.66). Increased sodium content of blood ves-
sels has been suggested as the possible mechanism for this
stiffness based on the observation that the vascular sodium
content of the large and small arteries of animals with heart
failure is higher. Furthermore. increased tissue pressure as-
sociated with apparent or subclinical edema may also be
contributory. Thus, there are several interacting mechanisms
that may contribute to the elevation of systemic vascular
resistance.
and minoxidil belong to this class. Other agents cause va-
sodilation by decreasing or inhibiting the vasoconstricting
effects mediated by the sympathetic adrenergic system. Drugs
like phentolamine. prazosin and trimazosin decrease vas-
cular tone and systemic vascular resistance primarily by
alpha-adrenergic blockade. Reduction of systemic vascular
resistance and arterial pressure also occurs after ganglionic
blockade with hexamethonium and trimethaphan, which
produce beneficial effects in heart failure. Beta--adrenergic
receptor stimulation also causes peripheral vasodilation. and
agents like salbutamol and pirbuterol appear to decrease
systemic vascular resistance by this mechanism. The prin-
cipal mechanism by which slow channel blocking agents
such as nifedipine cause vasodilation and reduction of sys-
temic vascular resistance is thought to be inhibition of the
inward calcium current to the smooth muscle of the vascular
bed. Prostacyclin and prostaglandin E increase cyclic aden-
osine monophosphate levels in the smooth muscle of the
vascular bed and cause vasodilation.
Because the renin-angiotensin-aldosterone system is fre-
quently activated and contributes to the increased systemic
vascular resistance seen in heart failure. inhibition of the
vasoconstricting effect of angiotensin II is a logical approach
for decreasing systemic vascular resistance and increasing
cardiac output. Saralasin is a competitive antagonist of an-
giotensin II. Captopril, teprotide and MK-42 I decrease the
formation of angiotensin II from angiotensin I by inhibiting
the converting enzyme. Attenuation of the effects of an-
giotensin II decreases arterial pressure and systemic vascular
resistance (66).
Many of these vasodilator drugs possess additional phar-
macologic properties that might be contributory to periph-
eral vasodilation. For example. although phentolamine is
an alpha-adrenergic blocking agent. it also directly relaxes
the smooth muscle of arteries and veins (47). Phentolamine
also possesses beta-adrenergic stimulating effects that may
contribute to peripheral vasodilation (67). Similarly, cap-
topril, in addition to decreasing the vasoconstricting effects
of angiotensin II, also inhibits the degradation of bradykinin.
a vasodilator that might also be contributory to reducing
systemic vascular resistance.
Site of action. Irrespective of their primary mechanisms
of vasodilation. the hemodynamic effects of the vasodilator
drugs appear to be related to their principal site of action
on the peripheral vascular bed. One group of vasodilators
predominantly dilates systemic veins (for example. nitro-
glycerin). a second group predominantly dilates arterioles
(for example. hydralazine) and a third group has a more or
less balanced effect on arteries and veins (for example.
nitroprusside). Vasodilators that predominantly dilate sys-
temic veins increase the volume of these capacitance vessels
and thus effectively redistribute circulating blood volume.
This results in a transient reduction in venous return, al-
though. as a new steady state level is reached. venous return
p
0.001
NS
0.001
NS
0.002
0.001
3.2 :+: 0.2
63 :+: 6
15
185 :+: 27
55 :+: 18
73 :+: 3
95 :+: 3
Coronary Artery
Disease Without
Heart Failure
2.1 :±: 0.2
22 :+: 3
9
520 :±: 72
45 :±: 8
95 :±: 5
89 :±: 6
Chronic
Congestive
Heart Failure
Data are mean values :t standard deviation.
NS = not significant: p = probability.
Number of patients
Arterial norepinephrine (pg/ml)
Arterial epinephrine (pg/ml)
Heart rate (beats/min)
Mean blood pressure (rnrn Hg)
Cardiac index (liters/min per
me)
Stroke work index (g-m/m')
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may be maintained or even increased if forward cardiac
output is also increased. However, this pooling of blood in
the veins is effective in reducing filling pressures and in-
tracardiac volumes of the right and left sides of the heart,
thus relieving pulmonary and systemic venous congestion.
Venous dilators. The effects of a predominant veno-
dilator drug on cardiac performance are also dependent on
the initial level of left ventricular filling pressure. If one
starts at a normal filling pressure, pooling of blood and a
further reduction of filling pressure will tend to lower stroke
volume as the ventricle moves down the ascending limb of
its curve (Fig. I). In order to maintain cardiac output under
these circumstances, there may be a compensatory increase
in heart rate. If one starts at a high filling pressure, a re-
duction in filling pressure will occur along the fiat portion
of the ventricular function curve and therefore will not produce
a marked reduction in ventricular performance. Thus, it is
apparent that caution should be taken in giving a venodilator
to a patient with a very low filling pressure. A further re-
duction in filling pressure may reduce forward stroke volume
and cardiac output to produce a precipitous fall in blood
pressure; this potential harmful effect must be considered
before administering any venodilator to a patient with a low
initial filling pressure, especially after acute myocardial
infarction.
Arteriolar vasodilators and drugs with combined ef-
fects. Vasodilators that primarily decrease arteriolar tone
cause a reduction in systemic vascular resistance and an
increase in cardiac output with little or no change in ven-
tricular filling pressures. Drugs with balanced effects on
arteriolar and venous beds decrease systemic vascular re-
sistance and systemic venous tone and cause an increase in
cardiac output and a decrease in ventricular filling pressures.
The net increase in cardiac output with these agents is
necessarily less than that expected from their arteriolar di-
lating effect because of the concomitant reduction of filling
pressure related to venodilation. None of the vasodilator
drugs currently available has pure arteriolar or venodilator
effects. The response of the peripheral vascular beds to
vasodilator agents in individual patients may be variable and
the hemodynamic effects of a given vasodilator agent may
not be identical in all patients. Moreover, the relative effects
of the vasodilator drugs on the systemic veins versus sys-
temic arteries cannot be assessed solely from changes in
right or left ventricular filling pressures and systemic vas-
cular resistance. Changes in right atrial and pulmonary ve-
nous pressures are related not only to the changes in ven-
tricular preload and afterload but also to the compliance
characteristics of the right and left ventricles and of the
pulmonary vascular bed. Thus, the preferential effects of a
vasodilator drug on arteries or veins should be assessed,
whenever possible, by direct determinations. Nevertheless,
a knowledge of the principal site of action on the peripheral
vascular beds provides the clinician with an understanding
of the expected hemodynamic effects of a vasodilator drug.
Hemodynamic Effects
Nitrates. The principal hemodynamic effects of the
commonly used vasodilator drugs for the treatment of acute
or chronic heart failure are summarized in Table 2. Nitrates,
whether administered sublingually , topically or intrave-
nously, tend to produce qualitatively similar hemodynamic
effects in patients with acute or chronic heart failure (68-
72). A reduction in pulmonary capillary wedge and right
atrial pressures is the most consistent effect. There is usually
a modest decrease in arterial pressure. Pulmonary artery
pressure and pulmonary vascular resistance tend to decrease
in most patients. Changes in systemic vascular resistance,
cardiac output and stroke volume are variable. However, a
very large oral dose of isosorbide dinitrate (100 mg) has
been reported to increase cardiac output considerably in
some patients with chronic heart failure (73).
Hydralazine and minoxidiI. By contrast, these drugs,
which are predominantly arteriolar dilators, cause a signif-
icant reduction in systemic vascular resistance and a marked
increase in cardiac output with little or no change in pul-
monary venous pressure (74-76). Arterial pressure is only
slightly decreased, and there is usually no change in heart
rate. However. in some patients. marked hypotension and
tachycardia may occur during hydralazine or minoxidil ther-
apy. Salbutamol, pirbuterol and nifedipine appear to produce
very similar hemodynamic effects (77-80).
Nitroprusside, phentolamine, prazosin, trimazosin and
captopriI. These vasodilator agents have a relatively bal-
anced effect on both arteriolar and venous beds; they de-
crease both afterload and preload. The usual hemodynamic
effects are a reduction of arterial pressure and systemic
vascular resistance and an increase in cardiac output and
stroke volume. Pulmonary capillary wedge, right atrial and
pulmonary artery pressures also decrease. Heart rate either
decreases or remains unchanged, even when there is a de-
crease in arterial pressure, except with phentolamine, which
tends to cause some tachycardia (8,28,36,58-60,81-95).
Despite the different mechanisms for vasodilation, these
agents produce qualitatively and quantitatively similar
hemodynamic effects. Nitroprusside, a direct vasodilator,
prazosin, an alpha-receptor blocking agent, and captopril,
an angiotensin-converting enzyme inhibitor, decrease sys-
temic and pulmonary venous pressures and increase cardiac
output concurrently. The hemodynamic effects outlined in
Table 2 are the usual and expected response to these vas-
odilator agents in patients with heart failure. Significant
variability, however. can be observed in different patients.
Comparative Hemodynamic Effects
To determine the relative advantages of the various vaso-
dilator agents that are potentially useful for the treatment
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Table 2. The Principal Hemodynamic Effects of Vasodilators Used for Treatment of Heart Failure
Systemic Pulmonary Right Pulmonary
Hearl Blood Cardiac Vascular Venous Atrial Vascular
Vasodilator Rate Pressure Output Resistance Pressure Pressure Resistance
Nitroglycerin No change Slight No change or No change or Marked Marked Decrease
decrease slight slight decrease decrease decrease
increase
Isosorbide No change Slight No change or No change or Marked Marked Decrease
dinitrate decrease slight slight decrease decrease decrease
increase
Hydralazine No change Slight Marked Marked decrease No change No change Slight
or slight decrease or increase or slight decrease
increase no change decrease
Minoxidil No change Slight Marked Marked decrease No change No change Slight
or slight decrease or increase or slight decrease
increase nochange decrease
Prazosin No change Moderate Moderate Moderate Marked Marked Decrease
or slight decrease increase decrease decrease decrease
decrease
Trimazosin No change Moderate Moderate Moderate Marked Marked Decrease
or slight decrease increase decrease decrease decrease
decrease
Captopril No change Moderate Moderate Moderate Marked Marked Decrease
or slight decrease increase decrease decrease decrease
decrease
Pirbuterol Increase or No change or Moderate Moderate Moderate Moderate Slight
no slight Increase decrease dec rease decrease decrease
change decrease
Salbutamol Increase or No change or Moderate Moderate No change No change Slight
no slight increase decrease or slight or slight decrease
change decrease decrease decrease
Nifedipine Increase or Decrease Increase Decrease Decrease or Decrease or Decrease
no no no
change change change
Nitroprusside Increase or Slight Increase Decrease Decrease Decrease Decrease
no decrease
change
Phentolamine Increase Slight Increase Decrease Decrease Decrease Decrease
decrease
of heart failure , it is necessary to evaluate the hemodynamic
effects of these agen ts in the same patients. Studies of hemo-
dynamic effects have been performed comparing hydrala-
zine with nitrates and nitroprusside , prazosin with nitro-
prusside and captopril , and nitroprusside with captopril.
Armstrong et al. (96) compared the hemodynamic effec ts
of both intravenous sodium nitroprusside and intravenou s
nitroglycerin in the same group of patients with acute myo-
cardial infarction. A greater incre ment in the ratio of sys-
temic vascular resistance to pulmonary capillary wedge
pressure was noted with nitroglycerin than with nitropru s-
side at a comparable decrease in arterial press ure. Stinson
et al . (97) compared the hemodynamic effects of intravenous
nitroglycerin and nitroprusside in early post-surgical pa-
tients. Although both drug s decreased left atrial pressure ,
nitroprusside increased stroke volume and cardiac output,
while nitroglycerin decreased cardiac output and stroke vol-
ume . Flaherty et al. (98 ), however. observed that at similar
levels of left ventricular filling pressure s in postoperative
patients there was no significant difference in the magnitude
of the increa se in cardiac output or stroke volume with
nitroglycerin or nitropru sside . These patients. however. did
not have pump failure. In most stud ies in patients with heart
failure, a greater increa se in cardiac output has been ob-
served with nitroprusside than with nitroglycerin. Awan et
al. (99) reported that the magnitude of increase in cardiac
output with captopril ( + 21 % ) was less than that with pra-
zosin ( + 30%l, although left ventricular filling pressure fell
by a similar magnitude (captopril - 29%, prazosin - 30% ).
Recently . Rouleau et al. (100 ) reponed the comparati ve
hemodynamic effects of captopril , prazosin and hydralazin e
in the same patients with chronic ischemic heart failure
(Table 3) . The magnitude of increase in cardiac output after
captopril (19c/c l was less than that with prazosi n (29%l or
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Captopril
(n = 8)
C
Peak
p
Prazosin
(n = 8)
C
Peak
p
Hydralazine
(n = 8)
C
Peak
p
HR
(beats/min)
90 ± 12
83 ±9
<0.05
89 ± 15
97 ± 13
<0.05
91 ± 14
94 ± 15
NS
Mean BP
(mm Hg)
83 ± 12
64 ± 12
<0.001
80 ± 8
62 ± 10
<0.001
77 ± 7
72 ± II
<0.025
Diastolic BP
(mm Hg)
62 ± 10
46 ± 8
<0.001
61 ± 5
46 ± 7
<0.001
57 ± 4
50 ± 8
<0.005
PCWP
(mm Hg)
23 ± 6
15 ± 4
<0.025
21 ± 7
13 ± 6
<0.005
21 ± 8
18 ± 7
<0.05
SWI
(g-rn/m')
29 ± 12
2lS ± 9
NS
26 ± 13
25 ± 9
NS
27 ± 12
34 ± 16
<0.01
CI
(liters/min per rrr')
2.1 ± 0.5
2.5 ± 0.4
<0.001
2.0 ± 0.5
2.7 ± 0.4
<0.001
2.1 ± 11
2.9 ± 0.7
<0.001
SVR
(dynes s-cm - 5)
1465 ± 258
938 ± 126
<0.001
1553 ± 379
lS63 ± 215
<0.001
1445 ± 279
955 ± 271
<0.005
Data are mean values ± standard deviation. Peak values indicate variables measured when there was a 10 mm Hg decrease in diastolic pressure.
C = control; CI = cardiac index; Diastolic BP = diastolic arterial pressure: HR = heart rate: Mean BP = mean arterial pressure; P = probability: PCWP = pulmonary
capillary wedge pressure; SVR = systemic vascular resistance; SWI = stroke work index.
Figure 2. Relative changes incardiac index, pulmonary capillary wedge
pressure (PCWP) and myocardial oxygen consumption (MV02) after
administration ofcaptopril, prazosin and hydralazine in patients with chronic
congestive heart failure. With all three agents, left ventricular pump func-
tion improved; however, only with captopril MV02 decreased significantly.
(Reprinted from Chatterjee K, Rouleau J-L [lOl], with permission.)
hydralazine (36%). However. heart rate decreased with cap-
topril, while it increased with both prazosin and hydralazine;
thus, the increase in stroke volume was similar with all three
agents-29, 24 and 34%, respectively. The decrease in
pulmonary capillary wedge pressure with captopril and pra-
zosin was considerably greater than with hydralazine (Fig.
2) (10I). In their study, the comparative hemodynamic ef-
fects were evaluated after a single dose of prazosin and
hydralazine. With continued administration of either agent
for 24 or 48 hours more pronounced differences in their
hemodynamic effects have been observed (102). The mag-
nitude of decrease in systemic vascular resistance was greater
with hydralazine (44%) than with prazosin (20%). Conse-
quently, the increase in cardiac output was also greater with
hydralazine (52%) than with prazosin. In this group of pa-
tients pulmonary capillary wedge pressure did not decrease
significantly either with prazosin or with hydralazine. The
lack of a significant reduction of pulmonary capillary wedge
pressure after hydralazine is expected because of its weak
venodilatory effects. It is not clear why there was no change
with prazosin; attenuation of the hemodynamic response
after subacute therapy remains a possible explanation.
Clinical Applications
In recent years vasodilator agents have been used for the
treatment of heart failure due to a variety of causes. Vas-
odilator therapy has gained acceptance in the management
of acute pump failure in patients with recent myocardial
infarction, in patients after cardiac surgery and in patients
with mechanical defects. There has been increasing interest
in the use of nonparenteral vasodilator agents for the long-
term management of patients with chronic congestive heart
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failure. The potential role of vasodilator agents for the ther-
apy of predominantly right heart failure associated with
pulmonary hypertension is currently under investigation.
Acute Myocardial Infar ction
Indications. In the management of pump failure com-
plicating recent myocardial infarction. intravenous vasodi-
lators with a rapid onset of action and short half-life are
preferable. Sodium nitroprusside, nitroglycerin and phen-
tolamine are the most frequently used vasodilator agents.
Since the initial report of Franciosa et al. (8). the hemo-
dynamic effects of sodium nitroprusside have been evalu-
ated in a number of studies (28.36,96,103) . These results
indicate that in the presence of an elevated left ventricular
filling pressure and reduced cardiac output, nitroprusside
therapy improves left ventricular function (Fig. 3) (30) .
Cardiac output and stroke volume increase along with a
decrease in left ventricular filling pressure. These beneficial
hemodynamic effects are usually accompanied by clinical
improvement and can be observed even in patients with
severe pump failure with or without the clinical features of
cardiogenic shock (Table 4) (10 3) . Sublingual nitroglycerin
and sublingual or oral isosorbide dinitrate also improve left
ventricular function in patients with acute myocardial in-
farction if the initial left ventricular filling pressure is ele-
vated (104-107 ). In patients with a normal left ventricular
filling pressure and no pump failure, cardiac output and
stroke volume may decrease as left ventricular fill ing pres-
sure decreases. indicating no improvement in cardiac func-
tion (108) .
Choice of vasodilator agent. Controversy exists re-
garding the choice of vasodilator agent for the treatment of
pump failure complicating myocardial infarction. In some
studies nitroglycerin has been shown to decrease the extent
of myocardial injury, and nitroprusside, to enhance myo-
cardial ischemia in the presence of experimental myocardial
infarction (36). Transmyocardial blood fl ow and subendo-
cardial blood flow to the ischemic myocardial segments
increased with nitroglycerin, and transmyocardial and sub-
endocardial blood flow decreased with nitroprusside. An
increase in collateral blood flow and decreased extravascular
components of the coronary vascular bed resistance have
been suggested as the likely mechanisms of enhanced per-
fusion to the ischemic myocardium with nitroglycerin. It
has also been suggested that vasodilators. such as nitro-
prusside, with arteriolar dilating effects are more prone to
cause diversion of blood flow from ischemic regions. This
" coronary steal" might enhance existing myocardial
ischemia and result in increased ST elevation or deterio-
ration in regional mechanical function (36,109-111). Con-
trary to these reports. increased regional blood flow to isch-
emic myocardial segments (presumably collateral blood flow)
associated with improved segmental myocardial function
has been observed during nitroprusside therapy (34). Fur-
thermore. improved regional metabolic function of
ischemic myocardium was reported during nitroprusside in-
fusion in experimental myocardial infarction ( 112. 113). The
effects of nitroprusside on the extent of myocardial injury
were compared with those of phentolamine in dogs with
experimental myocardial infarction. Nitroprusside de-
creased ischemic injury. but phentolamine enhanced it (1 14).
In animal models. nitroprusside was shown to increase sub-
endocardial blood flow provided that the initial left ven-
tricular fill ing pressure was elevated: in the absence of heart
failure. subendocardial blood flow decreased in the same
experimental models (37).
Clinical results. In patients with recent myocardial in-
farction, conflicting results were obtained with these va-
sodilator agents. In some investigations, nitroprusside caused
an increase in ST segment elevation and a higher level of
serum creatine kinase (CK), suggesting an extension of
myocardial injury (36.109.115 ). In other studies. however.
a "reduction" in infarct size, as determined by a decrease
in ST segment elevation, was noted (\ 16). Amelioration of
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Figure 3. Influence of nitroprusside infusion on left ventric-
ular function in patients with acute myocardial infarction.
Group I represents all patients with an initial left ventricular
filling pressure of less than 15 mm Hg. These patients did
not have pump failure . In Groups II and III. the patients had
left ventricular failure with filling pressures greater than 15
mm Hg. Initial stroke work index was greater than 20 g-m/
m2 in Group II and less than 20 g-m/rrr' in Group Ill. In these
two groups, nitroprusside infusion produced a redu ction in
filling pressure and an increase in stroke volume. In contrast .
Group I patients with a low filling pressure tended to have a
reduction in stroke volume and a reduction in filling pressure .
(Reprinted from Chatterjee K, Parmle y WW [30], with
permission. )
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Table 4. Hemodynamic Changes During Intravenous VasodilatorTherapy in Severe Pump Failure Complicating Acute Myocardial
Infarction (n = 43) (30)
Heart rate (beats/min)
Arterial pressure (rnm Hg)
Pulmonary artery pressure (mrn Hg)
Right atrial pressure (mm Hg)
Left ventricular filling pressure (mm Hg)
Cardiac index (liters/min per m~ j
Stroke volume index (ml/nr')
Stroke work index (g-m/nr')
Systemic vascular resistance (dynes cm - ~ )
All values are mean :t standard error of the mean.
Control
100 :: 2..+
83 ::': 1.5
39 :: 1.2
13 :: 0.8
31 :: 1.0
1.7 ::t 0.05
17.3 ::t 0.2
14 ::t 0.7
2023 ::t 112
Vasodilator
99 ::t 2.7
73 ::': 1.7
28 ::': 1.1
9 ::t 0.6
20 ::t 0.8
2.2 ::t 0.06
22.8 ::t 0 .8
19 ::t 0 .9
1435 :: 65
p
NS
< 0.0005
< 0.0005
< 0.0005
< 0.0005
< 0.0005
< 0.0005
< 0.005
< 0.0005
postinfarction angina associated with a reduction in the mag-
nitude of ST segment elevation was observed in some pa-
tients with acute myocardial infarction and persistent hy-
pertension (117). In prospective randomized studies. early
intervention (within 12 hours of the onset of symptoms)
with sodium nitroprusside was associated with lower peak
creatine kinase-MB isoenzyme levels compared with those
in the control group (118,119). A similar reduction in infarct
size calculated from CK and CK-MB activity curves was
observed with intravenous nitroglycerin in a prospective
randomized study (120). However, in a similar study. no
significant decrease in the CK-MB activity was noted in the
patients treated with nitroglycerin (121).
Effect 00 myocardial perfusion. It is apparent that both
nitroprusside and nitroglycerin have the potential to decrease
myocardial ischemia in appropriate subsets of patients with
acute myocardial infarction. Global myocardial oxygen con-
sumption tends to decrease and reduced relative ischemia
of noninfarcted ischemic myocardial segments might con-
tribute to improved left ventricular function. However. in
most patients there is a thrombotic occlusion of the stenosed
coronary artery supplying the infarcted territory. Increased
perfusion to the peri-infarction zones. therefore, can occur
only if there is an increase in collateral blood flow. Con-
troversy exists regarding the effects of vasodilator agents
on collateral flow, and to what extent vasodilators can in-
crease collateral blood fl ow to infarcting myocardial seg-
ments in patients with acute myocardial infarction is un-
known. Furthermore. it is not clear whether such an increase
in collateral flow is suffi cient to cause any significant de-
crease in the extent of myocardial injury. Decreased CK
activity and a reduction of ST segment elevation. which are
indicative of a reduction in myocardial injury. are not direct
evidence for increased myocardial perfusion. Moreover, de-
creased serum levels may be related to slower washout (122),
and the elevated ST segments may decrease spontaneously
without enhanced perfusion to the infarcting myocardial
segments. However. deep Q waves. the electrocardio-
graphic evidence of myocardial necrosis, may develop rap-
idly despite increased regional myocardial perfusion. as oc-
curs after coronary artery recanalization with thrombolytic
therapy. Thus, enzymatic or electrocardiographic methods
cannot conclusively show that vasodilator therapy decreases
the extent of myocardial injury in patients with myocardial
infarction.
Some reduction in arterial pressure usually occurs during
vasodilator therapy . If there is a marked reduction in arterial
pressure. particularly in patients with hypotension or nor-
motension. myocardial ischemia in patients with severe mul-
tivessel coronary artery disease is likely to be enhanced.
When the objective of treatment is to improve pump func-
tion. benefi cial hemodynamic effects of vasodilator therapy
occur in most patients without a significant reduction in
arterial pressure.
Prognosis Af ter Vasodilator Therapy in Patients
With Acute Myocardia/Infarction .
Nitroprusside. Recently the influence of nitroprusside
therapy on the mortality of patients with acute myocardial
infarction was evaluated in prospective randomized studies.
One group (I 18)reported a significant reduction in mortality
at I week, with a decreased incidence of clinical cardiogenic
shock and left ventricular failure after nitroprusside therapy.
Late mortality at weeks 2 through 4 was also less in the
nitroprusside-treated group. However. in the Veterans
Administration cooperative study (119). nitroprusside ther-
apy was not associated with any change in early or late
mortality. In patients with a transient elevation of left ven-
tricular filling pressure who received nitroprusside within 9
hours of the onset of symptoms. the early mortality was
greater than in those receiving placebo. However. in patients
with a persistent elevation of left ventricular filling pressure,
the hospital mortality was less in the nitroprusside-treated
group. Hockings et al. (123) found no reduction in hospital
mortality with nitroprusside therapy in patients with acute
myocardial infarction and an elevated left ventricular filling
pressure.
The reasons for the different results of these investiga-
tions are not obvious. In the study demonstrating a reduced
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mortality ( II HI. nitroprusside therapy was started relatively
earlier (mean 5 hours) after the onset of symptoms than in
the studies showing no benefi t. This suggests that nitro-
prusside may be effective in lowering mortality when given
early after the onset of infarction. but further confirmation
of these results is needed before the routine use of nitro-
prusside can be recommended in patients with acute myo-
cardial infarction. It should be noted that patients with severe
pump failure and cardiogenic shock were excluded from
randomization in these studies.
Intravenous nitroglycerin. In a few prospective ran-
domized studies. intravenous nitroglycerin was given to as-
sess its influence on the prognosis of patients with mild or
no left ventricular failure (120-1 24). Either no change or
a slight reduction in mortality was reported. In these studies.
however. the number of patients randomized was too small
to draw any definitive conclusion. Thus. no conclusive evi-
dence is available to suggest that the routine use of either
nitroprusside or nitroglycerin improves the prognosis of pa-
tients with relatively uncomplicated myocardial infarction.
Cardiogenic shock. No controlled study has been per-
formed to assess the effects of vasodilator therapy on the
prognosis of patients with severe pump failure or car-
diogenic shock. In an uncontrolled study. a lower hospital
mortality was reported with vasodilator therapy compared
with the expected mortality with conventional therapy (103).
Forty-three patients with severe pump failure were treated:
40 patients with nitroprusside and 3 patients with phen-
tolamine. Severe pump failure was defined on the basis of
initial hemodynamics, that is. an initial stroke work index
of 20 g-rn/rrr' or less and a left ventricular fill ing pressure
greater than 15 mrn Hg. Clinically, all patients had frank
pulmonary edema. Seventeen patients had clinical features
of cardiogenic shock. Initially. a beneficial hemodynamic
response was observed in almost all patients: cardiac output
increased. while pulmonary capillary wedge pressure de-
creased. Nineteen patients (44%) died in the hospital, 15
(34%) from uncontrolled pump failure. These findings sug-
gest a signifi cant improvement in the immediate prognosis
of patients with severe pump failure complicating myo-
cardial infarction. Although the efficacyof vasodilator ther-
apy cannot be fi rmly established without a control study. it
is supported by the improvement in prognosis compared
with reported mortality fi gures of approximately 75% with
conventional therapy (125.1 26). However. when the stroke
work index was extremely low (less than 10 g-m/rrr') and
the Icft ventricular filling pressure was elevated, the prog-
nosis was extremely poor. The mortality rate in this subset-
even with vasodilator therapy- was 82%. In these patients
the use of intraaortic balloon counterpulsation combined
with vasodilator and inotropic therapy was occasionally
effective.
Late prognosis. Despite an apparent improvement in the
initial prognosis of some patients with severe pump failure
treated with vasodilator therapy. the late prognosis remains
unfavorable in the survivors (103). Sixty-two percent of the
patients surviving initial hospitalization died within I to 25
months (average 9.2) after discharge. The projected 2 year
survival rate in these patients was only 289c . Currently. it
is uncertain whether any other therapy will significantly
improve the grave prognosis of these patients. Nevertheless.
more aggressive therapy like myocardial revascularization
with or without aneurysmectomy should be considered in
such patients.
Heart Failure Complicatin g Mechanical Defects
Clinical and hemodynamic improvement is observed during
vasodilator therapy in patients whose heart failure is pre-
cipitated or exacerbated by mechanical defects such as mitral
and aortic regurgitation and ventricular septal defect.
The severity ojmitral regurgi tation is related not only
to the degree of anatomic derangement of the mitral valve
apparatus but also to changes in the aortic impedance
(127. 128). An increase in left ventricular ejection imped-
ance is associated with an increased regurgitant volume and
decreased forward stroke volume and cardiac output. Va-
sodilator agents like sodium nitroprusside. hydralazine and
prazosin increase forward stroke volume and cardiac output
and decrease the regurgitant volume as the aortic impedance
decreases (9. 129.132). Decreased regurgitation is associ-
atcd with a decreased magnitude of the regurgitant V wave.
mean pulmonary capillary wedge and pulmonary artery
pressures (Fig. 4).
In patients with aortic regurgitation, sodium nitroprus-
side and hydralazine decrease regurgitant volume and in-
crease forward cardiac output because of a decreased left
ventricular ejection impedance ( 133- 135). Left ventricular
end-diastolic volume and pressure decrease. and the ejection
fraction increases. These benefi cial hemodynamic effects
are particularly seen in patients with an elevated left ven-
tricular fi lling pressure.
The magnitude of the lef t 10 right shunt due 10 a ven-
tricular septal defect is infl uenced by the size of the defect
and by the ratio of the pulmonary and systemic vascular
resistances ( 136) . Increased systemic vascular resistance is
associated with an increased shunt volume and a propor-
tional decrease in systemic output. Vasodilators like sodium
nitroprusside. hydralazine. phentolamine and phenoxyben-
zamine reduce the left to right shunt and increase the sys-
temic output by decreasing systemic vascular resistance
(137. 138). Pulmonary venous pressure and pulmonary ar-
tery pressure also decrease.
Clinical application. Although vasodilator agents produce
benefi cial hemodynamic effects. their clinical application in
the management of heart failure associated with mechanical
defects has not been clearly defined. In patients with severe
mitral regurgitation or ventricular septal rupture complicat-
VASODILATOR THERAPY
Figure 4. Hemodynamic effects of sodium nitro-
prusside in a patient with severe acute mitral regur-
gitation. Left ventricular pressure and pulmonary
capillary wedge pressure are illustrated in each panel.
On the left panel, note the large regurgitant V waves
(up to 70 mm Hg) in the pulmonary capillary wedge
pressure trace . During the admin istration of sodium
nitroprusside (right panel ) pulmonary capillary wedge
pressure and . left ventricular end-diastolic pressure
returned almost to the normal range and the regur-
gitant V waves essentiall y disappeared. This patient
illustrates the beneficial effects of vasodilator ther-
apy in patients with mitral regurgitation. (Reprinted
from Chatterjee K, Parmley WW [301, with
permission. )
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ing acute myocardial infarction , vasodilators such as nitro-
prus side or hydralazine can be used for immediate hemo-
dynamic and clinical improvement. However, vasodilator
therapy should be regarded as supportive rather than defin-
itive treatment; surgical correction should be considered as
soon as the patient's condition is stabilized .
In patients with bacterial endocarditis and acute mitral
or aortic regurgitation with heart failure, there is a potential
role for vasodilator therapy to tide the patient over the crit-
ical period until the infection is under control. Surgery should
not be delayed if there is an inadequate hemodynamic
response.
Long-term vasodilator therapy for mechanical defects is
occasionally indicated when surgical correction either is
contraindicated or needs to be deferred because of associated
noncardiac complications . Although vasod ilators may po-
tentially delay progressive ventricular dysfunction by de-
creasing left ventricular volume, regurgitant fraction and
left ventricul ar work , information is not available regarding
the effects of long-term vasodil ator therapy in patients with
mitral or aort ic regurgitation.
Chronic Congestive Heart Failure
Increased pulmonary venous pre ssure and low cardiac out-
put are the two important hemodynamic corre lates of the
major symptoms of patients with chronic congestive heart
failure. Dyspnea at rest or during physical activity is pri-
marily a result of an elevated pulmonary venous pressure,
and tiredness and fatigue are due to decreased cardiac out-
put. The two major hemod ynamic objectives of therapeutic
interventions in these patients are to increase cardiac output
and decrease pulmonary capillary wedge pressure . Intra-
venous va sodilators such as sodium nitroprusside or phen-
tolamine decrease pulmonary venous pre ssure and increase
cardiac output in patients with chronic heart failure (66, 139) .
However, intravenous vasod ilator therapy is applicable only
for short-term treatment or to determine the magnitude of
the hemodynamic response prior to initiat ion of long-term
vasodilator therapy .
Nitrates and hydralazine. Several vasodilators have been
investigated in the long-term management of heart failure
( 140) . Th e hemodynam ic effec ts of nitroglycerin and other
organ ic nitrates are similar and include a substantial reduc-
tion of right atria! and pulmonary capillary wedge pre ssures
with little or no increase in cardiac output (140). In some
studies, an increased cardiac output has been reported with
nitrates (70.73), but the magnitude of increase appears to
be sub stantially less than that expected with the use of a
predominantl y arteriolar dilator (141) . With the use of ar-
teriolar dilators , such as hydralazine and minoxidil, right
atrial and pulmonary capi llary wed ge pressures either re-
main unchanged or decrease onl y slightly. although card iac
output increases considerably. It is apparent that the com-
bination of an arteriolar dilator and a venodilator may pro-
vide hemodynamic advantages in the management of chronic
heart failure. The hemodynamic effect s of nonparenteral
nitrates alone , hydralazine alone and combined nitrate s and
hydralazine the rap y are illustrated in Figure 5 (141) .
Prazosin. Prazosin and trimazosin are post-synaptic al-
pha-receptor blocking age nts and produce beneficial hemo-
dynamic effects in patients with chroni c heart failure (86-
92). Both age nts cause a sig nificant reduction in sys temic
and pulm onary venous pressures and a substantial incre ase
in cardi ac output. A mode st decrease in mean arterial and
pulmonary artery pressure s , and in system ic and pulmonary
vascular resistances, also occurs; heart rate remains un-
changed (Ta ble 5 , Fig . 6) . In many patients , profound hy-
potension may occur after the first dose of prazosin : there-
fore, prazosin therapy should be started cautiously.
Controversy exists regardin g the continued efficacy of
prazosin . In some studies . marked attenuat ion of the hemo-
dynamic effec ts was observed within 48 to 72 hours (142).
Th e increased card iac output and decreased pulmonary cap-
illary wedg e pressure obse rved after the first dose were no
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Figure 5. The hemodynamic effects of nitrates alone (N),
hydralazine alone (H), and combined hydralazine and ni-
trates (N + H) in 12 patients with chronic congestive
heart failure. The administration of nitrates resulted in a
significant reduction in right atrial pressure and pulmonary
capillary wedge pressure. Hydralazine produced a marked
increase in cardiac index and a decrease in systemic vas-
cular resistance. The combined therapy produced a de-
crease in both ventricular filling pressures along with an
increase in cardiac index. Heart rate and arterial pressure
were virtually unaffected. Statistically significant changes
from control at the 0.01 and 0.001 levels are indicated by
* and **, respectively. (Reprinted with permission from
Chatterjee K. Massie B, Rubin S. et al. Long-term out-
patient vasodilator therapy of congestive heart failure. Am
J Med 1978:65:134-44.)
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longer present after the fifth dose, despite a similar plasma
concentration of the drug. Furthermore, the hemodynamic
response was not regained by increasing the dose. In con-
trast, sustained beneficial hemodynamic and clinical effects
of prazosin were reported in other investigations (143.144).
Improved ejection fraction determined by radioisotope an-
giography was observed during continued prazosin therapy.
The explanation for the different results in these studies is
not obvious. Blunting of the hemodynamic effects of pra-
zosin may occur only during subacute therapy (2 to 3 days),
and the hemodynamic response is regained if therapy is
continued for a longer period. It needs to be mentioned that.
in most studies in which a sustained effect was observed.
the dose of diuretic drugs was also increased. Increased
plasma volume was observed in hypertensive patients who
fail to respond to prazosin (145). Thus, decreased plasma
volume with larger doses of diuretics might have contributed
to the sustained hemodynamic effects of prazosin. Studies
show that the addition of antialdosterone agents is helpful
in maintaining the beneficial clinical response to prazosin
(146). Increased plasma norepinephrine levels that occur in
some patients during long-term prazosin therapy might also
be contributory to its attenuated hemodynamic effects (147).
Hydralazine. In a few studies, the hemodynamic effects
of long-term hydralazine therapy were evaluated, and a sus-
tained improvement in left ventricular function was seen
(\48,149). Withdrawal of hydralazine was associated with
hemodynamic deterioration and decreased cardiac perfor-
mance. Fluid retention and weight gain, however, occur in
some patients during maintenance hydralazine therapy and
additional diuretics are required to maintain the hemody-
namic and clinical response. Furthermore, tolerance to hy-
dralazine has occurred in some patients with chronic heart
failure (\50).
Captopril. Recently, there has been increasing interest
in using the angiotensin antagonists for the treatment of
chronic congestive heart failure. The hemodynamic effects
of the oral angiotensin-converting enzyme inhibitor, cap-
topril, were evaluated in a number of investigations
(60,93,95). A significant reduction in systemic vascular re-
sistance and an increase in cardiac output are consistently
found. In many patients, heart rate decreases initially. Thus,
Table 5. Hemodynamic Effects (mean ± SEM) of Oral Prazosin Hydrochloride (3, 4 and 5 mg) in Patients With Chronic
Congestive Heart Failure (102)
HR MAP MpAp LVFp RAP CI SVI SWI SVR pVR
(beats/min) (mm Hg) (rnm Hgj (mm Hg) (mm Hg) (liters/min per me) (rnl/rn') (g-rn/rn') (dynes s-cm ') (dynes s-cm ')
C 86 ± 7 87 ± 3 36 ± 2 24 ± I i2 ± I 2.0 ± 0.1 26 ± 2 22 ± 3 1776 ± 85 285 ± 40
p-3 mg 83 ± 4 80 ± 2 28 ± 2 19 ± 2 10 ± 2 2.5 ± 0.2 31 ± 2 26 ± 3 1373 ± 82 194 ± 41
p-4 mg 85 ± 5 84 ± 3 28 ± 2 19 ± 2 10 ± I 2.4 ± 0.2 29 ± 2 25 ± 3 1631 ± 167 222 ± 31
p-5 mg 87 ± 7 79 ± 3 28 ± 3 19 ± 2 8 ± I 2.5 ± 0.2 30 ± 3 25 ± 3 1410 ± 118 186 ± 29
C vs P C>P* C>pt C>P§ C>p§ C<PII C<P§ C>pR~
p-3 vs -4 vs -5 mg
'p < 0.05; tp < 0.025; §p < 0.001; lip < 0.005; ~p < 0.001.
C = controlhemodynamics before prazosin; CI = cardiac index; HR = heart rate; LVFP = left ventricular filling pressure; MAP = mean arterialpressure; MPAP =
meanpulmonary arterypressure;P = prazosin;pVR = pulmonary vascular resistance; RAP = rightatrial pressure: SVI = stroke volume index:SVR = systemicvascular
resistance; SWI = stroke work index.
Note that the hemodynamic responses to 3, 4 or 5 mg of prazosin were similar.
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Figure 6. Percent change from control in heart rate (HR), mean arterial
pressure (BP) . pulmonary capill ary wedge pressure (PCW). right atrial
pressure (RA) . stroke work index (SWI). cardiac index (CI) and systemic
vascular resistance (SVR) after trimazosin therapy in patients with chron ic
congestive heart failure. There was a significant increase in stroke work
index and card iac index while pulmonary capillary wedge pressure, right
atrial pressure and systemic vascular resistance decreased.
the average increase in stroke volume is usually greater than
the incre ase in cardiac output. Despite a reduction in arterial
pressure which occurs in almost all patients. left ventricular
stroke work index increases . In most patients, captopril
causes a mark ed decrease in pulmonary capillary wedge
pressure and right atrial and pulmonary artery pressure s ,
with a concom itant decline in pulm onary vascular resis-
tance. The hemodynamic effects. after a single oral dose
(25 mg ), usuall y last for 6 to 8 hours (Fig. 7).
The hemodynamic effects of25, 50 and 100 mg doses of
captopril were evaluated in the same patients with chronic
heart fa ilure, and the magnitude of the hemodynamic re-
sponse was similar (93) . Thu s, the left ventricular filling
pressure decreased by an average of 46% after the 25 mg
dose, and the decrease in filling pressure after 50 and 100
mg was similar. The average reduction in systemic vascular
resistance (- 41%), mean arter ial pressure (-23%) and
right atrial pressure (- 27%) after the 25 mg dose was
almost identi cal to that after the 50 to 100 mg dose . Thu s,
it seems that doses larger than 25 mg of captopril are usually
not required for the treatment of con gestive heart failure .
Maintenan ce captopril therapy appears to provide sus-
tained improvement in left ventricular fun ction in patients
with chronic heart failure. In one study (Table 6) (93) after
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the initiation of therapy, mean arterial pressure decre ased
by 2 1%, and at 8 weeks the decrease in arterial pressure
was of a similar magnitude . Initially, captopril increased
cardiac output by 21%. but at 8 week s a larger increase
(41%) was noted. The initial elevated stroke volume was
maintained during long-term therapy. Mean pulmonary ar-
tery. right atrial and pulm onary capillary wedge pres sure s
rema ined lower than control pressure s. Similarly, a per-
sistent decrease in systemic vascular resistance was also
observed.
Fluid retention is extremely uncommon during mainte-
nance captopril therapy. presumably related to the de-
creased aldos terone level secondary to reduced angiotensin
II. In many patients. reduction of the diuretic dosage is
required to prevent marked hypotension . During captopril
therapy , the serum potassium level tend s to increase. and
the need for potassium supplementation decreases. Lack of
fluid retent ion and reduction of the plasma aldosterone level
appear to be the major advantages of captopril over other
vasodilators in the long-term management of patients with
chronic heart failure. The major disadvantage is marked
hypoten sion which occurs in approximately 20% of pat ients ,
particularly after the first dose . Preliminary studies suggest
that a dose titration with the use of much smaller doses
(6.25 mg , for example) may help avoid sudden marked
hypotension (151).
Figure 7. Changes in cardiac output (CO) and pulmonary capillary wedge
pressure (PeW) after a single 25 mg dose of captopril in patients with
chronic congestive failure . Within a half hour . cardiac output increased
and pulmonary capillary wedge pressure fell and these hemodynamic changes
lasted for 6 to 8 hours. (Reprinted from Ader R. Chatterjee K. Ports T .
et al. (93). by permission of the American Heart Association. Inc . )
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Table 6. Hemodynamic Effects at the Initiation of and After 8 Weeks of Maintenance Captopril Therapy in Seven Patients With
Chronic Heart Failure (93)
p Value
Immediate Control vs Control vs
Control Response 8 Weeks immediate response 8 weeks
HR 78 ± 16 67 ± 15 73 ± 17 <0.05 <0.05
MAP 89 ± 16 70 ± 15 68 ± 9 <0.05 <0.05
PCW 29 ± 9 16 ± 4 13 ± 7 <0.05 <0.05
PAP 40 ± 10 28 ± 7 27 ± 14 <0.05 <0.05
RAP 12 ± 3 9 ± 3 5 ± 2 <0.05 <0.05
CO 3.54 ± 66 4.38 ± 1.30 5.09 ± 1.54 <0.05 <0.05
SV 46 ± 20 68 ± 22 72 ± 26 <0.05 <0.05
SWI 28 ± 12 36 ± 8 35 ± 7 NS NS
SVR 1933 ± 753 1175 ± 384 1084 ± 327 <0.05 <0.05
co = cardiac output (liters/min per rrr'): HR = heart rate (beats/min): MAP = mean artenal pressure (rnm Hg): PAP = mean pulmonary artery pressure (rnm Hgl;
PCW = pulmonary capillary wedge pressure (mm Hg): RAP = right atrial pressure (rnrn Hg): SV = stroke volume (rnl): SWI = stroke work index cg-m/m/j.
Another oral angiotensin-converting enzyme inhibitor,
MK-421 , is now under investigation; the preliminary results
suggest that its hemodynamic effects are similar to those of
captopril and it may also be useful in the long-term man-
agement of chronic congestive heart failure (152).
Effects on left ventricular function. The influence of
vasodilator therapy on left ventricular function of patients
with chronic heart failure during exercise has been evalu-
ated. Cardiac output and stroke volume remain elevated
during exercise after hydralazine therapy. although pul-
monary capillary wedge pressure tends to increase by a
similar magnitude with or without the addition of hydral-
azine to conventional therapy (153). Isosorbide dinitrate also
improves cardiac performance during exercise: cardiac out-
put increases and the exercise-induced elevation of pul-
monary capillary wedge pressure is less marked. Similarly.
with the addition of prazosin or trimazosin to conventional
therapy, the increase in cardiac output during exercise is
considerably greater than with conventional therapy (54).
Although pulmonary capillary wedge pressure increases. the
magnitude of increase is less with the addition of these
vasodilators to conventional therapy. An increase in left
ventricular ejection fraction during exercise determined by
gated blood pool scintigraphy has been observed after pra-
zosin therapy (144). Captopril produces beneficial hemo-
dynamic effects during exercise. Cardiac output and stroke
volume remain elevated and the left ventricular filling pres-
sure is lower. suggesting improved left ventricular function
during exercise (155). The radionuclide ejection fraction
increases after captopril both at rest and during exercise
(155). Thus. the cardiac performance of patients with chronic
heart failure tends to improve after vasodilator therapy. Ex-
ercise tolerance and oxygen consumption also increase but
usually not after short-term therapy. Long-term nitrate ther-
apy improves exercise tolerance and oxygen consumption.
Similarly, peak symptom-limited exercise capacity usually
increases after long-term hydralazine. prazosin, trimazosin
or captopril therapy (93.144,156.157).
Regional Hemodynamic Effects
Limb flow. A reduced cardiac output is accompanied
by changes in the perfusion of regional vascular beds. De-
creased limb and hepatic blood flow and a marked reduction
of renal plasma flow occur in patients with congestive heart
failure (158,159). Although cardiac output increases with
most vasodilator drugs. little information is available re-
garding the distribution of the increased cardiac output.
Vasodilators with arteriolar-dilating effects such as hydral-
azine and prazosin decrease limb vascular resistance and
augment limb blood flow at rest (160). It is unknown whether
a similar increase of flow occurs to the exercising limbs.
However, despite an increase in cardiac output. it seems
that the nutritional flow to the exercising skeletal muscles
does not increase after the short-term administration of either
hydralazine or prazosin (161). The peak serum lactate con-
centrations during exercise (at the same work load) were
similar before and after the addition of these vasodilators.
and the time constant for the lactate disappearance following
cessation of exercise did not change after acute prazosin or
hydralazine therapy. Similarly. during maximal and sub-
maximal exercise. the increase in arterial lactate and cate-
cholamine release were similar before and after the acute
administration of nitroglycerin (162). These findings suggest
that short-term vasodilator therapy does not increase nutri-
tional flow to exercising muscles. It is unknown whether
increased limb flow during exercise occurs after chronic
therapy.
Hepatic flow. Hepatic vascular resistance and hepatic
blood flow do not appear to change following the short-term
administration of hydralazine. despite a considerable in-
crease in cardiac output (160.163). Prazosin, on the other
hand. decreases hepatic vascular resistance and increases
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hepatic blood flow at smaller doses. With larger doses,
however, these effects are markedly attenuated (160 , 163).
Nitrates do not change hepatic blood flow in patients with
chronic heart failure. Hepatic blood fl ow tends to decrease
after captopril therapy. although cardiac output increases
significantly (164,168).
Renal flow. The effects of vasodilator drugs on renal
hemodynamics and function in the presence of chronic heart
failure have been the subject of several investigations. An
increased cardiac output with hydralazine is accompanied
by increased renal blood flow and decreased renal-vascular
resistance ( 160, 163. 165); these changes appear to be dose-
related. Glomerular filtration rate remains unchanged but
filtration fraction decreases. Excretion of sodium and po-
tassium is also enhanced in these patients after hydralazine
therapy.
Captopril tends to produce a marked increase in renal
blood flow along with an increased ratio of renal to systemic
blood flow in congestive heart failure. As with hydralazine,
the glomerular filtration rate does not change. but the fi l-
tration fraction decreases. Urinary sodium excretion in-
creases markedly along with decreased plasma aldosterone
and norepinephrine concentrations. It has been suggested
that converting-enzyme inhibition reverses renal vasocon-
striction in congestive heart failure and redistributes regional
blood flow. The increased urinary sodium excretion may be
related to improved renal plasma fl ow and a decreased plasma
aldosterone concentration. Decreased circulating catechol-
amines and a reduced filtration fraction might also be con-
tributa ry. If marked hypotension occurs with captopril. renal
function may not improve or may even deteriorate despite
increased cardiac output and improved left ventricular func-
tion 066, 167). Prazosin does not appear to affect renal blood
flow or renal vascular resistance acutely (163). Similarly.
isosorbide dinitrate does not alter renal hemodynamics and
renal function in patients with chronic congestive heart fail-
ure (160). It appears, therefore, that hydralazine and cap-
topril improve renal blood flow and renal function. which
might be an advantage in the treatment of patients with
chronic heart failure, associated with decreased renal function.
Coronary blood flow. In many patients with chronic
heart failure, obstructive coronary artery disease coexists.
Therefore, it is relevant to evaluate the changes in coronary
hemodynamics and myocardial metabolic function produced
by vasodilator drugs. In general, nitrates decrease coronary
blood flow and myocardial oxygen consumption. The de-
crease in myocardial oxygen consumption appears to be due
to a decrease in myocardial oxygen demand (101) .
The relative changes in coronary blood fl ow. myocardial
oxygen consumption and rate-pressure product following
captopril. prazosin, and hydralazine in patients with chronic
ischemic heart failure are illustrated in Figures 8 and 9 (100).
With captopril, the rate-pressure product (heart rate times
systolic blood pressure), a commonly used index of myo-
cardial oxygen demand. decreased in all patients; there was
a concomitant reduction in coronary blood flow and myo-
cardial oxygen consumption. Angiotensin II causes a sus-
tained vasoconstriction of the large conductance vessels but
a transient vasoconstriction of the smaller resistance vessels.
An attenuation of the effects of angiotensin with captopril
and the possible decrease in angiotensin-induced coronary
vasoconstriction. therefore, might be expected to preserve
autoregulation. However, it seems that the decrease in cor-
onary blood fl ow with captopril in patients with congestive
heart failure is largely produced by a reduction of the hemo-
dynamic determinants of myocardial oxygen demand.
With hydralazine, there was also a general correlation
between changes in coronary blood j iow. myocardial oxygen
consumption and chang es in myocardial oxygen demand .
In patients with cardiomyopathy without obstructive coro-
nary artery disease. hydralazine decreased coronary vascular
resistance and increased coronary blood flow. The increase
in coronary blood fl ow in these patients occurred without
any significant change in the rate-pressure product: also,
coronary sinus oxygen content was higher and myocardial
oxygen extraction was lower. These fi ndings suggest that,
in patients with heart failure and normal coronary arteries,
coronary blood flow might increase from primary coronary
vasodilation ( 169) . In patients with fi xed occlusive coronary
artery disease. however. changes in coronary blood flow
appear to be related to the changes in the determinants of
myocardial oxygen demand. Changes in coronary blood
flow and myocardial oxygen consumption parallel changes
in the rate-pressure product ( 100) .
With prazosin , no correlation has been fo und between
changes in coronary blood f low and myocardial oxygen
consumption and changes in the determinants of oxygen
demand. Despite a significant reduction in arterial pressure,
the rate-pressure product and left ventricular filling pressure,
coronary blood flow increased in many patients. In others,
coronary blood flow decreased together with a decreased
rate-pressure product. The mechanism of this divergent re-
sponse to prazosin remains unclear. Prazosin is a potent
post-synaptic alpha-adrenergic blocking agent. Therefore.
a primary decrease in coronary vascular resistance might
cause an increase in coronary blood fl ow despite decreased
myocardial oxygen demand. It is apparent that the effects
of these vasodilator agents on coronary hemodynamics can
be different although the systemic hemodynamic effects are
similar. Only captopril. however. consistently improved left
ventricular function at a decreased metabolic cost (Fig. 9).
Influence of Vasodilator Therapy on the Prognosis
of Patients With Chronic Refr actory Heart Failure
Mortality. The long-term prognosis of patients with se-
vere chronic congestive heart failure is extremely poor. In
patients with ischemic or nonischemic cardiomyopathy. the
mortality rates with conventional therapy ranged from 39
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Figure 8. Captopril decreased the coronary blood flow
in all but one patient and decrease d the rate-pressure
product in all II patients . Prazosin had no predictable
effect on the coronary blood flow. but decreased the
rate-pressure product in all II patients. Hydralazine
tended to change the coronary blood flow in the same
way it changed the rate-pressure product (r = 0.6 ,
P = 0.05). With all three drugs. the patients that
decreased their coronary blood flow produced the most
lactate (0). Individual responses at the peak effect of
each drug and the mean :t SEM are plotted for each
drug. (Reprinted from Rouleau J-L. Chatterjee K. Benge
W, Parmley WW, Hiramatsu B [I(0). by permission
of the American Heart Associat ion. Inc. )
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to 80% in the initia l I to 2 years' follow-up (170- 175). No
adequately controlled study has bee n performed to eval uate
the influence of vasodilator therapy on the long-term prog-
nosis of patient s with chronic heart fai lure . Uncontro lled
studies. however, suggest that the overall prog nosis remai ns
unfavorable , despite vasodilator therapy. An 80% mortality
rate at 20 month s has been repo rted in patients with severe
chronic heart failure (mo st patients were in New York Heart
Association class IV), despite combined prazosin and nitrate
therapy (146). In a similar uncontrolled study. no significan t
improvement in the overall mortality was observed in 56
patients treated with hydralazine and nitrates (176). The
mortali ty rates in this gro up at 6, 12 and 18 month s were
22 , 35 and 63%, respective ly. Sudden death occ urred in
more than 50% of pat ien ts who died of cardiac causes . Thus.
hydralazine and nitrate therapy did not improve the survival
rate in these patients compared with that expected with
conve ntional therapy. Certain subse ts of patients . however.
appeare d to have a better prognosis than others . The lack
of progressive heart fai lure, as judged cl inically . was as-
soc iated with a better prognosis, but hemodynam ic mea-
sureme nts were more helpful in assessi ng prog nosis . The
severity of depress ion of cardiac function based on hemo-
dynami c indexes before the instituti on of hydralazin e-n itrate
therapy was related to the long-term prognosis. Thu s, the
patients with a pulm onary capillary wedge pres sure of 30
mm Hg or more had a significantly grea ter mortali ty than
that of patien ts with lower initial pulm onary capillary wedge
pressures. Patient s with an initial stroke work index of 30
g-rn/rn" or less also had a higher mortality rate. The com-
binat ion of these two hemodynami c variables was better
correlated with the subsequent outcome. Thus. the surviva l
rate in patients with a stroke work index greater than 30
g-m/m - and a pulmonary capillary wedge pressure below 30
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Figure 9. With captopril, the decrease in myocardial
oxygen consumption paralleled the decrease in rate-
pressure product (r =0.6 . p = 0.05) . Prazosin had
no predictable effect on the myocardial oxyge n con-
sumption, despite decreasing the rate-pressure product
in these nine patients . Hydralazine tended to change
the myocardial oxygen consumption in the same way
as it changed the rate-pressure product (r = 0.06. p
= 0.1). With all three drugs. the patients that de-
creased their coronary blood flow the most produced
lactate (0). Individual responses at the peak effect of
each drug and the mean :t SEM are plotted for each
drug. (Reprinted from Rouleau J-L.Chatterjee K, Benge
W, Parmley WW, Hiramatsu B [1(0). by permission
of the American Heart Association. Inc.)
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mm Hg was 69% compared with only 31% in patients with
both a stroke work index of less than 30 g-m/rrr' and a
pulmonary capillary wedge pressure greater than 30 mm
Hg.
Hemodynamic improvement. The magnitude of hemo-
dynamic improvement during the initiation of vasodilator
therapy was also helpful in assessing long-term prognosis.
In the subset with a stroke work index greater than 30
g-m/m? and a pulmonary capillary wedge pressure of less
than 20 mm Hg after initiation of therapy, 75% of patients
survived. In contrast, only 14% of patients with a stroke
work index of less than 30 g-rn/rn?and a pulmonary capillary
wedge pressure higher than 20 mm Hg after vasodilator
therapy survived.
Although certain subsets of patients with chronic conges-
tive heart failure may have a better survival rate (176,177),
further long-term controlled studies are needed to assess the
prognosis with vasodilator therapy. Furthermore, results with
one vasodilator agent cannot be extrapolated when a dif-
ferent agent is used, because considerable differences exist
among agents in their systemic and regional hemodynamic
effects.
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